{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rinnerthaler G"],"funding":["mundipharma international"],"pagination":["17588359211042301"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8529308"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["<h4>Background</h4>Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combination with capecitabine in pre-treated patients with MBC.<h4>Patients and methods</h4>AGMT MBC-6 is a multicentre, open-label, single-arm phase II study in HER2-negative MBC. All patients were pre-treated with anthracyclines and/or taxans and had measurable disease. Patients received per os 1000 mg/m<sup>2</sup> capecitabine twice daily on days 1 to 14 in combination with 80 mg/m<sup>2</sup> bendamustine intravenously on days 1 and 8 of a 3-week cycle for a maximum of eight cycles, followed by a capecitabine maintenance therapy. The primary"],"journal":["Therapeutic advances in medical oncology"],"pubmed_title":["Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)."],"pmcid":["PMC8529308"],"funding_grant_id":["unrestricted grant"],"pubmed_authors":["Hubalek M","Petru E","Petzer A","Schmitt CA","Ulmer H","Greil R","Balic M","Hauser-Kronberger C","Andel J","Melchardt T","Gampenrieder SP","Sandholzer M","Rinnerthaler G"],"additional_accession":[]},"is_claimable":false,"name":"Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).","description":"<h4>Background</h4>Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combination with capecitabine in pre-treated patients with MBC.<h4>Patients and methods</h4>AGMT MBC-6 is a multicentre, open-label, single-arm phase II study in HER2-negative MBC. All patients were pre-treated with anthracyclines and/or taxans and had measurable disease. Patients received per os 1000 mg/m<sup>2</sup> capecitabine twice daily on days 1 to 14 in combination with 80 mg/m<sup>2</sup> bendamustine intravenously on days 1 and 8 of a 3-week cycle for a maximum of eight cycles, followed by a capecitabine maintenance therapy. The primary","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-05-09T03:43:51.523Z","creation":"2025-02-19T01:44:28.997Z"},"accession":"S-EPMC8529308","cross_references":{"pubmed":["34691243"],"doi":["10.1177/17588359211042301"]}}